Primer Capital
Primer Capital is a venture capital firm based in Moscow, Russia, that specializes in early-stage investments in the healthcare, pharmaceutical, and biotechnology sectors. Established in 2015, the firm primarily focuses on projects related to oncology, cardiology, rheumatology, surgery, medical devices, and drugs, including generic and biosimilar products. Primer Capital typically invests between $0.2 million and $0.5 million and is open to co-investments alongside other venture capital funds and investors. The firm benefits from a team of qualified consultants and a Scientific Advisory Board composed of experts in various medical and biopharmaceutical fields, which enhances its project selection process. Primer Capital collaborates with venture capital partners, business angels, and governmental agencies to promote the development of the biopharmaceutical industry and support its portfolio companies in establishing effective partnerships and securing additional funding throughout their growth trajectory.
Nelo Mobile, S.A. de C.V. is a financial technology company based in Mexico City that specializes in digital payment solutions. Established in 2019, Nelo offers a mobile application compatible with Android and iOS devices, enabling users to conduct financial transactions such as sending and requesting money without fees. The platform also features a Nelo Mastercard debit card, which allows users to manage their funds securely while providing real-time tracking of transactions. Nelo's services are designed to facilitate affordable financial management, appealing to individuals seeking a convenient and cost-effective way to handle their finances.
MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing microbiome therapies specifically for dermatology and skin care. Headquartered in La Jolla, California, the company offers its lead product, MSB-01, a topical antimicrobial live bio therapeutic aimed at treating atopic dermatitis by restoring the necessary skin bacteria for effective host defense. In addition to therapeutics, MatriSys develops cosmetic ingredients derived from proprietary bacterial strains to address various skin conditions, including scaling, redness, and signs of aging. The company is exploring commercialization avenues across dermatology, skin care, and cosmetic sectors, with its lead therapeutic currently undergoing Phase I/II clinical trials. MatriSys aims to enhance skin health by rebalancing the skin's microbiome, promoting beneficial microbes while targeting harmful species.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.
MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing microbiome therapies specifically for dermatology and skin care. Headquartered in La Jolla, California, the company offers its lead product, MSB-01, a topical antimicrobial live bio therapeutic aimed at treating atopic dermatitis by restoring the necessary skin bacteria for effective host defense. In addition to therapeutics, MatriSys develops cosmetic ingredients derived from proprietary bacterial strains to address various skin conditions, including scaling, redness, and signs of aging. The company is exploring commercialization avenues across dermatology, skin care, and cosmetic sectors, with its lead therapeutic currently undergoing Phase I/II clinical trials. MatriSys aims to enhance skin health by rebalancing the skin's microbiome, promoting beneficial microbes while targeting harmful species.
Acticor Biotech SAS is a biotechnology company based in Paris, France, focused on developing therapeutic monoclonal antibodies for acute thrombotic diseases, particularly ischemic stroke. The company's lead product, Glenzocimab, is a humanized antibody aimed at addressing the critical need for new treatment options in the acute phase of stroke. Stroke affects approximately 15 million people worldwide each year, resulting in significant mortality and disability. Current treatment options are limited, with only one recommended therapy that benefits a small percentage of patients, highlighting the urgent demand for more effective solutions. Acticor Biotech was founded in 2013 and aims to provide innovative therapies that can significantly improve outcomes for stroke patients.
GemoPharm is a biotechnology company focused on developing innovative therapies for cancer treatment, particularly targeting relapsed or refractory primary and secondary central nervous system lymphomas and intraocular lymphomas. Its lead asset is a monoclonal antibody derived from a proprietary therapeutic platform that selectively targets CD71 in the tumor microenvironment. This targeted approach aims to reduce potential toxicities associated with non-selective treatments, and preclinical studies have demonstrated significant efficacy and validated the mechanism of action for the lead candidate. GemoPharm has successfully completed pilot toxicology studies, showing no signs of toxicity. Additionally, the company is also engaged in creating humanized antibodies with high antitumor activity and low toxicity to treat conditions like multiple myeloma, utilizing cellular and biomolecular processes to enhance the immune response against infections.
MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrate high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports the individualization of such treatment. MT-Medicals is based in Hefei City, Anhui Province, China.
Bendit Technologies Ltd. is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology to enhance steering capabilities in both micro and conventional catheter wires. Founded in 2013 and headquartered in Petach Tikva, Israel, the company focuses on creating small and flexible microcatheters designed for optimal navigation through vessels with complex anatomies. Bendit's products aim to improve the precision of medical procedures by enabling doctors to direct the catheters effectively, thereby minimizing risks and enhancing success rates. The company's expertise is bolstered by a joint venture of experienced professionals from production, quality, regulation, and development sectors within the medical field.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
DataMatrix is software that helps its users in organizing and managing clinical research. It processes data, analyzes it, and develops documents to be accepted by the Ministry of Health of Russia, FDA, and EMA. Its products also automate the processes of clinical trial, the users manage and monitor its progress online. Data Matrix was founded in 2009 in St.Petersburg, Russia.
Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.
FK Laboratoriz
Seed Round in 2016
FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.
Solo is a service for personalized anticancer therapy selection.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.